|

ASL in Brain Metastasis MRI Following Gamma Knife Treatment

RECRUITINGN/ASponsored by Assistance Publique - Hôpitaux de Paris
Actively Recruiting
PhaseN/A
SponsorAssistance Publique - Hôpitaux de Paris
Started2023-01-24
Est. completion2028-09-24
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04833335

Summary

Arterial spin labeling (ASL) is a non-invasive MRI technique that could help the radiologists to distinguish brain metastasis progression versus radionecrosis following gamma-knife treatment. The primary target of the study is to establish the diagnostic performances (specificity, sensitivity) of quantitative measures of ASL in brain metastases suspected of progression/radionecrosis after GK treatment

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Brain metastasis from histologically proven tumor
* GK treatment within 4 month prior to the inclusion
* Lesions suspected of progression/ radionecrosis :

  i.e.≥ 25% of the size progression
* Lesion size: gadolinium enhanced part of the tumour ≥1 cm

Exclusion Criteria:

* Pregnancy
* Medical history of primitive brain tumour
* MRI incompatibility/ medical history of contrast agent allergy
* Claustrophobia
* Patient unable to consent
* Epilepsia/recent stroke
* Patients participating in other studies
* Patients without health care insurance

Conditions2

Brain MetastasesCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.